BIOSINO BIO-TEC (08247) announced that on February 11, 2026, the company formally entered into a strategic cooperation agreement with Guangdong Xiaoshou Medical Technology Co., Ltd. The partnership, signed in Beijing, aims to foster multi-dimensional collaboration in the primary healthcare sector, focusing on channeling high-quality medical resources to grassroots levels and improving the capabilities of basic medical services.

According to the agreement, the two parties will explore cooperation in the following areas: 1. **Capital and Strategic Synergy:** BIOSINO BIO-TEC plans to make a strategic investment in Xiaoshou Medical to establish a long-term, stable strategic relationship. The companies will explore deepening their cooperation through capital ties and jointly investigate innovative development models for the primary healthcare market. 2. **Business and Resource Complementarity:** The Group will leverage its product advantages and research and development capabilities in the In-Vitro Diagnostic (IVD) field. This will be combined with Xiaoshou Medical's nationwide network of primary healthcare channels and its digital platform to deliver biochemistry, immunology, POCT products, and integrated solutions directly to grassroots medical institutions. Under the premises of compliance and data desensitization, both parties will also enhance collaboration on data insights, product development, and supply chain optimization. A joint task force will be established to develop customized products and integrated "Smart Laboratory Solutions" tailored for primary healthcare scenarios. 3. **Ecosystem and Value Co-creation:** By integrating multi-dimensional resources including equipment, reagents, operations, and data, the partnership will provide one-stop laboratory service solutions for regional healthcare consortiums and chain clinics. This initiative is designed to improve the overall testing capabilities and operational efficiency of primary medical institutions.

The cooperation will be implemented in phases, progressing steadily from initial strategic pilot verification to large-scale deployment, with further exploration of deep synergy at both industrial and capital levels.

The Board of Directors believes that this strategic cooperation with Xiaoshou Medical will assist the Group in integrating high-quality R&D capabilities with digital channel resources. It is expected to accelerate the penetration of the Group's products and services into primary healthcare institutions, aligning with the national strategy to advance the construction of the primary healthcare system and the "Healthy China" initiative. The Board is confident that the proposed collaboration under the agreement will help expand the Group's market coverage, enhance brand influence and long-term competitiveness, and is in the overall interests of the company and its shareholders.